|
Volumn 6, Issue 12, 2000, Pages 4674-4683
|
Phase I clinical trial of the chimeric monoclonal antibody (c30.6) in patients with metastatic colorectal cancer
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CHIMERIC ANTIBODY;
HISTAMINE H1 RECEPTOR ANTAGONIST;
HISTAMINE H2 RECEPTOR ANTAGONIST;
MONOCLONAL ANTIBODY;
ADULT;
AGED;
ANTIBODY RESPONSE;
ANTIGEN EXPRESSION;
ANTIGEN RECOGNITION;
ARTICLE;
CLINICAL ARTICLE;
CLINICAL TRIAL;
COLORECTAL CANCER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG BLOOD LEVEL;
DRUG DISTRIBUTION;
DRUG HALF LIFE;
DRUG INDUCED DISEASE;
DRUG SAFETY;
ERYTHEMA;
FEMALE;
HUMAN;
IMMUNOGENICITY;
MALE;
METASTASIS;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
ADULT;
AGED;
ANIMALS;
ANTIBODIES, MONOCLONAL;
CHO CELLS;
CHROMATOGRAPHY;
CHROMATOGRAPHY, GEL;
COLORECTAL NEOPLASMS;
CRICETINAE;
DOSE-RESPONSE RELATIONSHIP, DRUG;
ENZYME-LINKED IMMUNOSORBENT ASSAY;
FEMALE;
HUMANS;
IODINE RADIOISOTOPES;
LIVER;
MALE;
MICE;
MIDDLE AGED;
NEOPLASM METASTASIS;
TIME FACTORS;
TOMOGRAPHY, EMISSION-COMPUTED;
TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;
TOMOGRAPHY, X-RAY COMPUTED;
TREATMENT OUTCOME;
|
EID: 0034487408
PISSN: 10780432
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (6)
|
References (31)
|